Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:30 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Phase 2 Dose-finding IMU-838 for Ulcerative Colitis
NCT03341962 · Immunic AG · PHASE2 · terminated · last registry update 2024-03-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Considering the efficacy results of the induction phase (allowed use of corticosteroids as concomitant medication) in the study population and since IMU-838 did not show superiority over placebo, the OLE was prematurely closed by the sponsor.” | – | Registry record, Immunic AG |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against DHODH within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-01-14Results posted on the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Teriflunomide + Evobrutinib (NCT04338061)
- 2024-11-13Results posted on the registry: Immunic AG, IMU-838 (NCT04379271)
- 2024-10-29Phase 3 first posted: University Hospital, Strasbourg, France, treatment withdrawal + Usual DMT continuation (NCT06663189)
- 2024-04-17Phase 3 first posted: Sanofi, Tolebrutinib + Placebo (NCT06372145)
- 2023-11-21Phase 3 first posted: Sanofi, Frexalimab + Teriflunomide (NCT06141473)
- 2023-11-07Also stopped (terminated): Clear Creek Bio, Inc., Brequinar Sodium + Dipyridamole 75 MG (NCT05166876)
- 2023-06-26Results posted on the registry: PTC Therapeutics, PTC299 + Placebo (NCT04439071)
- 2023-06-26Also stopped (terminated): PTC Therapeutics, PTC299 + Placebo (NCT04439071)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision